These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

828 related items for PubMed ID: 15017527

  • 1. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
    Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L.
    Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
    [Abstract] [Full Text] [Related]

  • 2. [Risk and prevention of diabetic nephropathy].
    Ravera M, Re M, Deferrari G.
    G Ital Nefrol; 2007 Mar; 24 Suppl 38():13-9. PubMed ID: 17922442
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.
    Presse Med; 2002 Nov 09; 31(36):1714-20. PubMed ID: 12467154
    [Abstract] [Full Text] [Related]

  • 6. The RAAS in the pathogenesis and treatment of diabetic nephropathy.
    Ruggenenti P, Cravedi P, Remuzzi G.
    Nat Rev Nephrol; 2010 Jun 09; 6(6):319-30. PubMed ID: 20440277
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y, Huang R, Kavanagh J, Li L, Zeng X, Li Y, Fu P.
    Am J Cardiovasc Drugs; 2019 Jun 09; 19(3):259-286. PubMed ID: 30737754
    [Abstract] [Full Text] [Related]

  • 8. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT, Ribeiro AB.
    Clin Ther; 2002 Jul 09; 24(7):1019-34. PubMed ID: 12182249
    [Abstract] [Full Text] [Related]

  • 9. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C, Pöss J, Böhm M.
    Drugs; 2010 Jul 09; 70(10):1215-30. PubMed ID: 20568830
    [Abstract] [Full Text] [Related]

  • 10. Recommendations for the management of special populations: renal disease in diabetes.
    Raij L.
    Am J Hypertens; 2003 Nov 09; 16(11 Pt 2):46S-49S. PubMed ID: 14625161
    [Abstract] [Full Text] [Related]

  • 11. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U, Chaisuvannarat V.
    J Med Assoc Thai; 2009 May 09; 92(5):611-7. PubMed ID: 19459520
    [Abstract] [Full Text] [Related]

  • 12. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH.
    Horm Metab Res; 2005 Apr 09; 37 Suppl 1():4-8. PubMed ID: 15918104
    [Abstract] [Full Text] [Related]

  • 13. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ, Lewis JB.
    Clin Exp Nephrol; 2003 Mar 09; 7(1):1-8. PubMed ID: 14586737
    [Abstract] [Full Text] [Related]

  • 14. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
    Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving HH.
    Kidney Int; 2002 Jul 09; 62(1):192-8. PubMed ID: 12081578
    [Abstract] [Full Text] [Related]

  • 15. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
    Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH.
    Kidney Int; 2003 May 09; 63(5):1874-80. PubMed ID: 12675866
    [Abstract] [Full Text] [Related]

  • 16. Losartan in diabetic nephropathy.
    Perico N, Ruggenenti P, Remuzzi G.
    Expert Rev Cardiovasc Ther; 2004 Jul 09; 2(4):473-83. PubMed ID: 15225108
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade.
    Parvanova A, Chiurchiu C, Ruggenenti P, Remuzzi G.
    Expert Opin Pharmacother; 2005 Sep 09; 6(11):1931-42. PubMed ID: 16144512
    [Abstract] [Full Text] [Related]

  • 18. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH.
    Kidney Int; 2000 Feb 09; 57(2):601-6. PubMed ID: 10652037
    [Abstract] [Full Text] [Related]

  • 19. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L, Kocks MJ, Laverman GD, Navis G.
    Minerva Med; 2004 Oct 09; 95(5):395-409. PubMed ID: 15467515
    [Abstract] [Full Text] [Related]

  • 20. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 09; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.